Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14

Kingsberg, Sheryl A.; Althof, Stanley E.; Simon, James A.; Bradford, Andrea; Bitzer, Johannes; Carvalho, Joana; Flynn, Kathryn E.; Nappi, Rossella E.; Reese, Jennifer Barsky; Rezaee, Roya L.; Schover, Leslie R.; Shifrin, Jan L.

doi:10.1016/j.jsxm.2017.05.018

Cited by 75 publications

(40 citation statements)

References 185 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kingsberg et al recently provided an extensive overview of the psychosocial and pharmacologic (hormonal and nonhormonal) treatments for FSD, including those for HSDD, female sexual arousal disorder, and female orgasmic disorders, and found treatments in this area are severely lacking. 41 There is currently one FDA-approved treatment for HSDD (flibanserin) and no approved treatments for arousal or orgasmic disorders. Although the indicated population for flibanserin in HSDD is currently limited to premenopausal women only, data showed that flibanserin improved sexual function in postmenopausal women with HSDD.…”

Section: Factors Contributing To Suboptimal Sexual Health Outcomes Inmentioning

confidence: 99%

Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient–Clinician Communications

Kingsberg

Schaffir

Faught

et al. 2019

Journal of Women's Health

Self Cite

111

View full text Add to dashboard Cite

Background: Although sexual health can be considered a vital sign for overall health, several barriers prevent women from receiving proper medical counseling, support, and/or care for their sexual health needs and concerns. Methods: Experts in sexual health compiled research and experience on the impediments to women receiving adequate assessment and treatment for their sexual health. Specific solutions and a roadmap for overcoming such barriers and improving patient–clinician communication are presented. Results: Social stigma around female sexuality remains in Western culture and as a result, women often avoid and/or are embarrassed to discuss their sexual health with their health care professionals (HCPs). Moreover, midlife women are typically unaware or have misconceptions about conditions that may adversely impact their sexual life, such as genitourinary syndrome of menopause and hypoactive sexual desire disorder. Without understanding there may be underlying medical conditions, there is also a lack of awareness that safe and effective treatments are available. Lack of training, tools, time, and limited treatment options impede HCPs from providing women with necessary sexual health support. Educating women, training HCPs, and providing communication tools to HCPs can facilitate effective dialog between patients and HCPs. More specifically, HCPs can be trained to initiate and maintain a sexual health conversation in a manner that is comfortable for women to convey sexual health needs and concerns, and for HCPs to correctly identify, diagnose, and treat the sexual problems of their female patients. Conclusions: Solutions exist to address the barriers currently impeding patient–clinician interactions around sexual health.

show abstract

Section: Factors Contributing To Suboptimal Sexual Health Outcomes Inmentioning

confidence: 99%

Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient–Clinician Communications

Kingsberg

Schaffir

Faught

et al. 2019

Journal of Women's Health

Self Cite

111

View full text Add to dashboard Cite

show abstract

“…The neurological status should also be established. The International Index of Erectile Function (IIEF) and the Female Sexual Function Index (FSFI) are the most widely accepted validated questionnaires for evaluating erectile dysfunction and female sexual dysfunction, respectively [32, 33]. In men, the physical examination should seek penile deformities and signs of hypogonadism.…”

Section: Resultsmentioning

confidence: 99%

Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis

et al. 2019

View full text Add to dashboard Cite

Purpose We aimed to review the current knowledge on the epidemiology, diagnosis, and management of urinary and sexual dysfunction in patients with TTR amyloidosis (ATTR). Methods We performed a review of the literature, screening for randomized controlled trials, prospective and retrospective series, position papers, and guidelines on urinary and sexual dysfunction in ATTR patients published in PubMed and Embase. Results Lower urinary tract dysfunction is present in up to 83% of patients with ATTR. Voiding symptoms are the most common, reported in 34.8−87.5% of patients, while urinary tract infections are reported in up to 50%. Urinary incontinence is observed in 16.7−37.5% of the ATTR population, mostly due to decreased urethral resistance. Sexual dysfunction affects over 40% of ATTR patients, with erectile dysfunction and sexual arousal disorder being the most common symptoms in male and female patients, respectively. In addition to a thorough clinical examination, invasive pressure-flow urodynamic testing is a cornerstone in the assessment of ATTR lower urinary tract dysfunction. The most common finding is detrusor underactivity and intrinsic sphincter deficiency. Poor bladder compliance can also be observed in patients, due to amyloid deposits on the bladder wall. Urinary tract imaging may be of interest to rule out upper urinary tract deterioration. Given the paucity of data in the ATTR population, treatment should be tailored to the individual patient. Conclusion Urinary and sexual dysfunction are highly prevalent in ATTR patients. Comprehensive assessment and multidisciplinary management are keys to avoiding upper urinary tract damage and improving patients' quality of life.

show abstract

“…Psychotherapy includes educational intervention, counseling, and sensate focus therapy in a couple-based approach. 47 Sexual skills training, cognitive behavioral therapy, and marital therapy as psychological interventions improved symptom severity and sexual satisfaction. 48…”

Section: Psychosocial Treatmentsmentioning

confidence: 99%

Female Sexual Dysfunction in Women with Pelvic Pain

Tam¹,

Levine

2018

Semin Reprod Med

View full text Add to dashboard Cite

A variety of conditions can give rise to the perception of painful sexual intercourse in women with pelvic pain. Female sexual dysfunction may stem from psychological, medical such as endocrinological disturbances, and gynecological pathologies. This article provides a discussion of various conditions, offering diagnostic and therapeutic measures to consider in women with pelvic pain experiencing sexual dysfunction. Treatment and management options are also reviewed.

show abstract

Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14

Cited by 75 publications

References 185 publications

Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient–Clinician Communications

Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient–Clinician Communications

Diagnosis and treatment of urinary and sexual dysfunction in hereditary TTR amyloidosis

Female Sexual Dysfunction in Women with Pelvic Pain

Contact Info

Product

Resources

About